

DAFTAR PUSTAKA

- Acheampong, T. *et al.* (2020) "Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US from 2010 to 2016," *JAMA Network Open*, 3(8), p. E2013226. Available at: <https://doi.org/10.1001/jamanetworkopen.2020.13226>.
- Al-Keilani, M.S. *et al.* (2021) "Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index," *PLoS ONE*, 16(6 June). Available at: <https://doi.org/10.1371/journal.pone.0252616>.
- Al-Keilani, M.S. *et al.* (2023) "Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival," *BMC Cancer*, 23(1). Available at: <https://doi.org/10.1186/s12885-023-10633-8>.
- Arnold, M. *et al.* (2022) "Current and future burden of breast cancer: Global statistics for 2020 and 2040," *Breast*, 66, pp. 15–23. Available at: <https://doi.org/10.1016/j.breast.2022.08.010>.
- Botteri, E. *et al.* (2025) "Aprepitant use during chemotherapy and association with survival in women with early breast cancer.," *Journal of the National Cancer Institute*, 117(11), pp. 2249–2258. Available at: <https://doi.org/10.1093/jnci/djaf178>.
- Cheang, M.C.U. *et al.* (2009) "Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer," *Journal of the National Cancer Institute*, 101(10), pp. 736–750. Available at: <https://doi.org/10.1093/jnci/djp082>.
- Chen, X.Y. *et al.* (2016) "High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis," *OncoTargets and Therapy*, 9. Available at: <https://doi.org/10.2147/OTT.S102356>.
- Colomer, R. *et al.* (2024) "Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology," *Clinical and Translational Oncology*, 26(12), pp. 2935–2951. Available at: <https://doi.org/10.1007/s12094-024-03541-1>.
- Coveñas, R. and Muñoz, M. (2014) "Cancer progression and substance P," *Histology and Histopathology*, 29(7), pp. 881–890. Available at: <https://doi.org/10.14670/HH-29.881>.
- Cserni, G. *et al.* (2018) "The new TNM-based staging of breast cancer," *Virchows Archiv*, 472(5), pp. 697–703. Available at: <https://doi.org/10.1007/s00428-018-2301-9>.
- Davey, M.G. *et al.* (2021) "Ki-67 as a prognostic biomarker in invasive breast cancer," *Cancers*, 13(17). Available at: <https://doi.org/10.3390/cancers13174455>.
- Davoodian, M. *et al.* (2019) "Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer," *Molecular Biology Reports*, 46(1), pp. 1285–1293. Available at: <https://doi.org/10.1007/s11033-019-04599-9>.

- Ebrahimi, S. *et al.* (2020) "New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs," *Clinical Genetics*, 98(4), pp. 322–330. Available at: <https://doi.org/10.1111/cge.13750>.
- Garcia-Recio, S. *et al.* (2013) "Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer," *Cancer Research*, 73(21), pp. 6424–6434. Available at: <https://doi.org/10.1158/0008-5472.CAN-12-4573>.
- Höller, A. *et al.* (2023) "Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?," *Breast Cancer: Targets and Therapy*, 15, pp. 525–540. Available at: <https://doi.org/10.2147/BCTT.S340741>.
- Houcine, Y.O.L.D.E.Z. *et al.* (2025) "Concordance Of Scarff-Bloom And Richardson Grade Between Microbiopsy And Resection Specimen," *International Journal of Gynecological Cancer*, 35(2). Available at: <https://doi.org/10.1016/j.ijgc.2024.101237>.
- Huang, J. *et al.* (2021) "Global incidence and mortality of breast cancer: a trend analysis," *AGING*, 13(4).
- Inic, Z. *et al.* (2014) "Difference between Luminal A and Luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information," *Clinical Medicine Insights: Oncology*, 8, pp. 107–111. Available at: <https://doi.org/10.4137/CMO.S18006>.
- Inwald, E.C. *et al.* (2013) "Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry," *Breast Cancer Research and Treatment*, 139(2), pp. 539–552. Available at: <https://doi.org/10.1007/s10549-013-2560-8>.
- Jafarinezhad, S. *et al.* (2023) "The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses," *Cell Biochemistry and Biophysics*, 81(4), pp. 787–794. Available at: <https://doi.org/10.1007/s12013-023-01171-y>.
- Kasangian, A.A. *et al.* (2017) "The prognostic role of tumor size in early breast cancer in the era of molecular biology," *PLoS ONE*, 12(12). Available at: <https://doi.org/10.1371/journal.pone.0189127>.
- Liang, Q. *et al.* (2020) "Effect of Ki-67 Expression Levels and Histological Grade on Breast Cancer Early Relapse in Patients with Different Immunohistochemical-based Subtypes," *Scientific Reports*, 10(1). Available at: <https://doi.org/10.1038/s41598-020-64523-1>.
- Ma, Q. *et al.* (2024) "The Role of Ki-67 in HR+/HER2-Breast Cancer: A Real-World Study of 956 Patients," *Breast Cancer: Targets and Therapy*, 16. Available at: <https://doi.org/10.2147/BCTT.S451617>.
- Mashaghi, A. *et al.* (2016) "Neuropeptide substance P and the immune response," *Cellular and Molecular Life Sciences*, 73(22), pp. 4249–4264. Available at: <https://doi.org/10.1007/s00018-016-2293-z>.
- Mayordomo, C. *et al.* (2012) "Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2," *Journal of Cellular Physiology*, 227(4), pp. 1358–1366. Available at: <https://doi.org/10.1002/jcp.22848>.

- Mehboob, R. *et al.* (2021) "Prognostic Significance of Substance P/Neurokinin 1 Receptor and Its Association with Hormonal Receptors in Breast Carcinoma," *BioMed Research International*, 2021. Available at: <https://doi.org/10.1155/2021/5577820>.
- Menon, G., Alkabban, F.M. and Ferguson, T. (2024) "Breast Cancer," *Breast Cancer. StatPearls Publishing*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK482286/>.
- Muñoz, M. and Coveñas, R. (2013) "Involvement of substance P and the NK-1 receptor in cancer progression," *Peptides*, 48, pp. 1–9. Available at: <https://doi.org/10.1016/j.peptides.2013.07.024>.
- Muñoz, M. and Coveñas, R. (2014) "Involvement of substance P and the NK-1 receptor in human pathology," *Amino Acids*, 46(7), pp. 1727–1750. Available at: <https://doi.org/10.1007/s00726-014-1736-9>.
- Nascimento, R.G. do and Otoni, K.M. (2020) "Histological and molecular classification of breast cancer: what do we know?," *Mastology*, 30. Available at: <https://doi.org/10.29289/25945394202020200024>.
- Padmanaban, V. *et al.* (2024) "Neuronal substance P drives metastasis through an extracellular RNA-TLR7 axis.," *Nature*, 633(8028), pp. 207–215. Available at: <https://doi.org/10.1038/s41586-024-07767-5>.
- Pirić, M. *et al.* (2024) "Ki-67 and Histological Grade in Breast Cancer," *Open Access Macedonian Journal of Medical Sciences*, 12. Available at: <https://doi.org/10.3889/oamjms.2024.11974>.
- Prat, A. *et al.* (2015) "Clinical implications of the intrinsic molecular subtypes of breast cancer," *Breast*, 24, pp. S26–S35. Available at: <https://doi.org/10.1016/j.breast.2015.07.008>.
- Provenzano, E., Ulaner, G.A. and Chin, S.F. (2018) "Molecular Classification of Breast Cancer," *PET Clinics*, 13(3), pp. 325–338. Available at: <https://doi.org/10.1016/j.cpet.2018.02.004>.
- Rakha, E.A. *et al.* (2010) "Breast cancer prognostic classification in the molecular era: the role of histological grade," *Breast Cancer Research*, 12(4).
- Rakha, E.A., Tse, G.M. and Quinn, C.M. (2023) "An update on the pathological classification of breast cancer," *Histopathology*, 82(1), pp. 5–16. Available at: <https://doi.org/10.1111/his.14786>.
- Rodríguez, F. and Coveñas, R. (2022) "The Neurokinin-1 Receptor: Structure Dynamics and Signaling," *Receptors*, 1(1), pp. 54–71. Available at: <https://doi.org/10.3390/receptors1010004>.
- Rodriguez, F.D. and Covenas, R. (2024) "Association of Neurokinin-1 Receptor Signaling Pathways with Cancer," *Current Medicinal Chemistry*, 31(39), pp. 6460–6486. Available at: <https://doi.org/10.2174/0929867331666230818110812>.
- Sánchez, M.L. *et al.* (2025) "The Involvement of the Peptidergic Systems in Breast Cancer Development," *Cancers*, 17(22), p. 3662. Available at: <https://doi.org/10.3390/cancers17223662>.

- Schank, J.R. and Heilig, M. (2017) "Substance P and the Neurokinin-1 Receptor: The New CRF," *International Review of Neurobiology*. Academic Press Inc., pp. 151–175. Available at: <https://doi.org/10.1016/bs.irn.2017.06.008>.
- Siagian, D., Adnyana, I.M.O. and Widyadharma, I.P.E. (2020) "KADAR SUBSTANSI P SERUM TINGGI SEBAGAI FAKTOR RISIKO CHRONIC TENSION TYPE HEADACHE PADA MAHASISWA FAKULTAS KEDOKTERAN UNIVERSITAS UDAYANA," *Neurona*, 37.
- Smolarz, B., Zadrożna Nowak, A. and Romanowicz, H. (2022) "Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)," *Cancers*, 14(10). Available at: <https://doi.org/10.3390/cancers14102569>.
- Suvas, S. (2017) "Role of Substance P Neuropeptide in Inflammation, Wound Healing, and Tissue Homeostasis," *The Journal of Immunology*, 199(5), pp. 1543–1552. Available at: <https://doi.org/10.4049/jimmunol.1601751>.
- Taneja, P. *et al.* (2010) "Classical and novel prognostic Markers for Breast cancer and their Clinical Significance," *Clinical Medicine Insights: Oncology*, 2010, p. 4. Available at: <http://www.la-press.com>.
- Teichgraeber, D.C., Guirguis, M.S. and Whitman, G.J. (2021) "Breast cancer staging: Updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging," *American Journal of Roentgenology*, 217(2), pp. 278–290. Available at: <https://doi.org/10.2214/AJR.20.25223>.
- Turner, K.M. *et al.* (2021) "Heterogeneity within molecular subtypes of breast cancer," *American Journal of Physiology - Cell Physiology*, 321(2), pp. C343–C354. Available at: <https://doi.org/10.1152/ajpcell.00109.2021>.
- Wang, Y. *et al.* (2020) "Identification of Tumor Microenvironment-Related Prognostic Biomarkers in Luminal Breast Cancer," *Frontiers in Genetics*, 11. Available at: <https://doi.org/10.3389/fgene.2020.5558>